What are the long-term risks of Adalimumab injections?

Adalimumab is a biological agent widely used in the treatment of autoimmune diseases and is a tumor necrosis factor alpha (TNF-α) inhibitor. It helps relieve symptoms of rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and other diseases by inhibiting the inflammatory response in the body. Although adalimumab is effective in controlling disease activity, long-term use still carries certain risks and requires close attention by patients and doctors.

First, long-term use of adalimumab may increase the risk of infection. Because it suppresses immune system function, patients are more susceptible to bacterial, viral and fungal infections, especially tuberculosis and other opportunistic infections. Therefore, comprehensive infection screening, especially for tuberculosis, needs to be performed before treatment, and signs of infection need to be monitored regularly during treatment. If symptoms of infection are found, they should be treated promptly and adjustments to the medication regimen should be considered.

Secondly, long-term use of adalimumab may cause immune system-related side effects. For example, some patients may develop immune-mediated diseases, including systemic lupus erythematosus-like syndrome, hematological abnormalities (such as leukopenia), etc. In addition, in rare cases, patients may be at increased risk of malignancy, especially lymphoma, but this risk is low and requires a comprehensive evaluation of the patient's overall condition.

Finally, injection site reactions and allergic reactions also need attention. Long-term injections of adalimumab may cause redness, swelling, pain, or induration at the injection site, sometimes accompanied by allergic reactions such as rash. Although most reactions are mild, occasionally severe allergic reactions may occur and require immediate medical attention. During the medication process, patients should strictly follow the doctor's instructions for injections and follow up regularly to ensure the safe use of the medication.

In summary, although adalimumab brings significant curative effects to a variety of autoimmune diseases, long-term use still requires vigilance against infection, immune side effects, and injection-related reactions. Patients should take medications under the guidance of professional doctors, conduct relevant examinations regularly, detect and deal with adverse reactions in a timely manner, and ensure medication safety and therapeutic effects to the greatest extent.

Reference materials:https://www.drugs.com/donanemab.html